Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $135.27 USD
Change Today +3.60 / 2.73%
Volume 411.1K
BLUE On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 5:20 PM 04/21/15 All times are local (Market data is delayed by at least 15 minutes).

bluebird bio inc (BLUE) Snapshot

Open
$132.48
Previous Close
$131.67
Day High
$136.40
Day Low
$132.05
52 Week High
04/21/15 - $136.40
52 Week Low
05/9/14 - $17.40
Market Cap
4.4B
Average Volume 10 Days
476.1K
EPS TTM
$-1.75
Shares Outstanding
32.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BLUEBIRD BIO INC (BLUE)

bluebird bio inc (BLUE) Related Businessweek News

No Related Businessweek News Found

bluebird bio inc (BLUE) Details

bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Its advanced product candidate is Lenti-D, which is in phase II/III clinical studies for the treatment of childhood cerebral adrenoleukodystrophy, a rare, hereditary neurological disorder affecting young boys; and LentiGlobin that is in phase I/II clinical studies for the treatment of beta-thalassemia major and severe sickle cell disease (SCD) in France, as well as a phase I study in the United States for the treatment of severe SCD. The company also develops various CAR T cell products for liquid and solid tumor cancers. bluebird bio, Inc. has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.

143 Employees
Last Reported Date: 02/25/15
Founded in 1992

bluebird bio inc (BLUE) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $392.5K
Chief Operating Officer
Total Annual Compensation: $321.7K
Chief Scientific Officer
Total Annual Compensation: $307.2K
Compensation as of Fiscal Year 2013.

bluebird bio inc (BLUE) Key Developments

bluebird bio, Inc. Announces Resignation of Dr. Robert L. Tepper as Board of Director

On March 18, 2015, Dr. Robert L. Tepper notified bluebird bio, Inc. of his resignation from the company's board of directors, effective immediately. Dr. Tepper's resignation was not caused by any disagreement with the company on any matter relating to the company's operations, policies or practices.

bluebird bio, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015

bluebird bio, Inc. Presents at 3rd Annual Regen Med Investor Day, Mar-25-2015. Venue: Metropolitan Club, One East 60th Street, New York, NY 10022, United States. Presentation Date & Speakers: Mar-25-2015, James M. DeTore, Chief Financial Officer and Treasurer, Rick Morgan, Vice President of Immunotherapy.

bluebird bio, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

bluebird bio, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported total revenue of USD 6,386,000 against USD 6,335,000 a year ago. Loss from operations was USD 19,616,000 against USD 8,115,000 a year ago. Loss before income taxes was USD 19,544,000 against USD 8,081,000 a year ago. Net loss was USD 19,544,000 against USD 8,081,000 a year ago. Basic and diluted net loss per share was USD 0.67 against USD 0.34 a year ago. For the nine months, the company reported total revenue of USD 25,421,000 against USD 20,181,000 a year ago. Loss from operations was USD 60,626,000 against USD 24,947,000 a year ago. Loss before income taxes was USD 60,506,000 against USD 25,321,000 a year ago. Net loss was USD 48,709,000 against USD 25,321,000 a year ago. Basic and diluted net loss per share was USD 1.83 against USD 2.02 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BLUE:US $135.27 USD +3.60

BLUE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Fibrocell Science Inc $4.00 USD -0.04
Sangamo BioSciences Inc $14.40 USD +0.25
View Industry Companies
 

Industry Analysis

BLUE

Industry Average

Valuation BLUE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 152.1x
Price/Book 8.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 150.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BLUEBIRD BIO INC, please visit www.bluebirdbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.